Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer
Many genomic assays that assess recurrence risk in early breast cancer (EBC) are prognostic, but they differ in risk group stratification, which can affect clinical utility. Prospective outcomes of >60 K patients treated based on the 21-gene assay results have shown that chemotherapy may be safel...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
17 January 2019
|
| In: |
International journal of cancer
Year: 2019, Jahrgang: 145, Heft: 4, Pages: 882-893 |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.32139 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1002/ijc.32139
|
| Verfasserangaben: | Zsuzsanna Varga, Peter Sinn, Andrew D. Seidman |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1669227707 | ||
| 003 | DE-627 | ||
| 005 | 20220816192413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190716s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijc.32139 |2 doi | |
| 035 | |a (DE-627)1669227707 | ||
| 035 | |a (DE-599)KXP1669227707 | ||
| 035 | |a (OCoLC)1341233795 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Varga, Zsuzsanna |e VerfasserIn |0 (DE-588)1134998198 |0 (DE-627)889959609 |0 (DE-576)489625703 |4 aut | |
| 245 | 1 | 0 | |a Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer |c Zsuzsanna Varga, Peter Sinn, Andrew D. Seidman |
| 264 | 1 | |c 17 January 2019 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.07.2019 | ||
| 520 | |a Many genomic assays that assess recurrence risk in early breast cancer (EBC) are prognostic, but they differ in risk group stratification, which can affect clinical utility. Prospective outcomes of >60 K patients treated based on the 21-gene assay results have shown that chemotherapy may be safely omitted in EBC patents with low Recurrence Score (RS) results (RS < 18). Because of its extensive validation and wide clinical use, the RS assay is a common comparator in head-to-head studies with other assays. Published/presented studies of the RS assay performed on the same tumor samples with Breast Cancer Index (BCI), EndoPredict (EP) or EP+ clinical features (EPclin), MammaPrint (MMP) and/or Prosigna (ROR) assays were reviewed. Study findings were summarized descriptively. | ||
| 650 | 4 | |a breast cancer | |
| 650 | 4 | |a multigene tests | |
| 650 | 4 | |a risk score comparison | |
| 700 | 1 | |a Sinn, Peter |d 1957- |e VerfasserIn |0 (DE-588)1022590944 |0 (DE-627)717004783 |0 (DE-576)365646342 |4 aut | |
| 700 | 1 | |a Seidman, Andrew D. |e VerfasserIn |0 (DE-588)1190668475 |0 (DE-627)1669228436 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d Bognor Regis : Wiley-Liss, 1966 |g 145(2019), 4, Seite 882-893 |h Online-Ressource |w (DE-627)269532781 |w (DE-600)1474822-8 |w (DE-576)079876129 |x 1097-0215 |7 nnas |a Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer |
| 773 | 1 | 8 | |g volume:145 |g year:2019 |g number:4 |g pages:882-893 |g extent:12 |a Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijc.32139 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190716 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1022590944 |a Sinn, Peter |m 1022590944:Sinn, Peter |d 910000 |d 912000 |e 910000PS1022590944 |e 912000PS1022590944 |k 0/910000/ |k 1/910000/912000/ |p 2 | ||
| 999 | |a KXP-PPN1669227707 |e 3493610173 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"family":"Varga","given":"Zsuzsanna","role":"aut","display":"Varga, Zsuzsanna"},{"display":"Sinn, Peter","role":"aut","family":"Sinn","given":"Peter"},{"given":"Andrew D.","family":"Seidman","role":"aut","display":"Seidman, Andrew D."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 16.07.2019"],"id":{"doi":["10.1002/ijc.32139"],"eki":["1669227707"]},"physDesc":[{"extent":"12 S."}],"relHost":[{"origin":[{"dateIssuedKey":"1966","dateIssuedDisp":"1966-","publisher":"Wiley-Liss","publisherPlace":"Bognor Regis"}],"titleTranslated":[{"translated":"Journal international du cancer"}],"recId":"269532781","corporate":[{"role":"isb","display":"International Union against Cancer"}],"part":{"extent":"12","pages":"882-893","volume":"145","issue":"4","year":"2019","text":"145(2019), 4, Seite 882-893"},"note":["Gesehen am 28.02.08","Darin: Predictive oncology"],"titleAlt":[{"title":"Predictive oncology"}],"pubHistory":["1.1966 -"],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"International journal of cancer","title_sort":"International journal of cancer","subtitle":"publication of the International Union against Cancer (UICC) = Journal international du cancer"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"disp":"Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancerInternational journal of cancer","id":{"doi":["10.1002/(ISSN)1097-0215"],"eki":["269532781"],"issn":["1097-0215"],"zdb":["1474822-8"]}}],"name":{"displayForm":["Zsuzsanna Varga, Peter Sinn, Andrew D. Seidman"]},"origin":[{"dateIssuedDisp":"17 January 2019","dateIssuedKey":"2019"}],"title":[{"title_sort":"Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer","title":"Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer"}],"recId":"1669227707"} | ||
| SRT | |a VARGAZSUZSSUMMARYOFH1720 | ||